It was an on-again, off-again couple of weeks for one of the world’s largest drug makers.
On Aug. 13, the U.S. Court of Appeals for the D.C. Circuit suspended the Food and Drug Administration’s decision to approve generic versions of Eloxatin, a cancer drug manufactured by Paris-based Sanofi-Aventis that generated $1.9 billion in worldwide sales last year. By Tuesday, the suspension was called off, meaning that Sanofi’s competitors were free to start shipping and marketing their copies of the medication in the United States.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
